| Theme | Diagnostic Strategy for Early Stage Pancreatic Cancer | |
|---|---|---|
| Title | Catastrophic Hypothesis of Pancreatic Cancer -- Human Pancreatic Cancer and Pancreatic Cancer Mouse Models | |
| Publish Date | 2016/12 | |
| Author | Takashi Yamaguchi | Biotechnology Research Institute for Drug Discovery, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology (Present address : Department of Molecular and Tumor Pathology, Graduate School of Medicine |
| Author | Sanae Ikehara | Biotechnology Research Institute for Drug Discovery, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology |
| Author | Yuzuru Ikehara | Biotechnology Research Institute for Drug Discovery, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology / epartment of Molecular and Tumor Pathology, Graduate School of Medicine, Chiba University |
| [ Summary ] | A characteristic feature of pancreatic ductal adenocarcinoma (PDAC) is a poor clinical course, called "catastrophic progression," that recalls the de novo carcinogenesis pathway. PDAC arises from pancreatic intraepithelial neoplasia (PanIN) as a pre‒cancerous lesion in a multi‒step manner. One essential point of catastrophic progression is whether the characteristic feature is confined to the end point of the PanIN‒PDAC linear pathway, or can be extended to the de novo carcinogenesis pathway. From this viewpoint, we will provide an overview of the clinicopathological features of PDAC and genetically engineered mouse models (GEMs) that develop PDAC. We will provide an outline of the mouse models of pancreatic cancer, and then discuss the possibility of the presence of a "catastrophic progression without a pre‒cancerous lesion" |
|